SCHEMBL23037243

SCHEMBL23037243

Nc1nnc(Cl)cc1N1CCC(O)CC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 9/20 0.57
SMARCA2 P51531 7/20 0.57
SMARCA4 P51532 6/20 0.57
NR1I2 O75469 2/20 0.38
PTPN11 Q06124 1/20 0.37
HTT P42858 3/20 0.36
ALDH1A1 P00352 1/20 0.36
ATR Q13535 1/20 0.36
ATRIP Q8WXE1 1/20 0.36
CDK1 P06493 1/20 0.36
CDK2 P24941 1/20 0.36
STK4 Q13043 1/20 0.36
STK3 Q13188 1/20 0.36
LRRK2 Q5S007 1/20 0.36
LMNA P02545 2/20 0.34
SMPD3 Q9NY59 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
SMO Q99835 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31179821 1.00 PBRM1 (0.57) PBRM1SMARCA2SMARCA4NR1I2PTPN11
SCHEMBL30667470 0.83 PBRM1 (0.42) PBRM1SMARCA2SMARCA4NR1I2ATR
SCHEMBL15687937 0.81 SMARCA2 (0.50) PBRM1SMARCA2SMARCA4NR1I2HTT
SCHEMBL18038817 0.80 SMARCA2 (0.51) PBRM1SMARCA2SMARCA4NR1I2HTT
SCHEMBL23751677 0.79 SMARCA2 (0.38) PBRM1SMARCA2SMARCA4HTTLMNA
SCHEMBL23037203 0.79 PBRM1 (0.38) PBRM1SMARCA2SMARCA4NR1I2HTT
SCHEMBL29943433 0.78 DHFR (0.54) PBRM1SMARCA2SMARCA4NR1I2
SCHEMBL23037212 0.78 MEN1 (0.60) HTTALDH1A1ATRLMNA
SCHEMBL22959766 0.77 SMARCA2 (0.54) PBRM1SMARCA2SMARCA4ALDH1A1
SCHEMBL1819342 0.77 MAPT (0.51) PBRM1SMARCA2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371426-B2 Pyridazine derivatives as SMARCA2/4 degraders AURIGENE DISCOVERY TECH LTD (IN) 2025-07-29 US disclosed
US-20240270734-A1 Pyridazine Derivatives as SMARCA2/4 Degraders Aurigene Oncology Technologies Limited (IN) 2024-08-15 US disclosed
US-20210253564-A1 Pyridazine Derivatives as SMARCA2/4 Degraders AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2021-08-19 US disclosed
US-20210253564-A1 Pyridazine Derivatives as SMARCA2/4 Degraders AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2021-08-19 US disclosed
CN-112771038-A Pyridazine derivatives as SMARCA2/4 degradants 奥里吉恩发现科技有限公司 2021-05-07 CN disclosed
EP-3784665-A1 PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS Aurigene Discovery Technologies Limited (IN) 2021-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270734-A1 Pyridazine Derivatives as SMARCA2/4 Degraders SMARCC1, SMARCC2, SMARCA2 PBRM1 37/4885SMARCA2 3/4885SMARCA4 5/4885
US-12371426-B2 Pyridazine derivatives as SMARCA2/4 degraders SMARCC1, SMARCC2, SMARCA2 PBRM1 37/4885SMARCA2 3/4885SMARCA4 5/4885
US-20210253564-A1 Pyridazine Derivatives as SMARCA2/4 Degraders SMARCC1, SMARCC2, SMARCA2 PBRM1 37/4885SMARCA2 3/4885SMARCA4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.